Healthcare investors are watching AstraZeneca closely after fresh comments about operating at Chinese speed, reaffirming a 2030 sales goal of $80b and reporting 6% revenue growth at constant exchange rates in the first half of 2026, even as the Wainua trial setback put its pipeline under scrutiny. This mix of confidence, competition from China and pressure to accelerate drug development could reshape how large pharmaceutical and biotechnology stocks are viewed. This article walks through 3 stocks from the Healthcare Innovation Leaders screener that appear particularly exposed to these news driven shifts.

Krystal Biotech (KRYS)

Overview: Krystal Biotech is a Pittsburgh based commercial biotech company focused on genetic medicines, led by its FDA approved gene therapy VYJUVEK for dystrophic epidermolysis bullosa and a pipeline that spans eye disease, cystic fibrosis, oncology, skin disorders and aesthetic skin treatments.

Operations: Krystal Biotech generated US$417.3m from the discovery, development, manufacturing and commercialization of genetic medicines, with all revenue currently coming from the United States.

Market Cap: US$9.9b

Krystal Biotech gives investors exposure to an approved gene therapy with high unmet medical need, expanding global launches and a growing pipeline in areas like ophthalmology, cystic fibrosis and lung cancer that aligns with AstraZeneca’s push for faster, high impact drug development. Some analysts note that the stock trades at a valuation that certain models suggest is below estimated fair value, even with a higher than average P/E. The main risks are heavy reliance on VYJUVEK, potential quarter to quarter revenue swings and recent insider selling, which together raise questions about how much of the company’s prospects are already reflected in the price and how durable its performance might be if competition or regulation tightens.

Krystal Biotech’s gene therapy story looks powerful, but the real tension is how much of VYJUVEK’s potential and the wider pipeline is already priced in. The 3 key rewards and 1 important warning sign starts to unpack this before a key twist investors often miss.

TG Therapeutics (TGTX)

Overview: TG Therapeutics is a commercial stage biopharmaceutical company based in North Carolina that develops and sells treatments for B cell mediated diseases. The business is led by its multiple sclerosis drug BRIUMVI and a pipeline that includes antibody therapies and a CAR T program aimed at autoimmune and blood disorders.

Operations: TG Therapeutics generates about US$700.3m in revenue from its biotechnology activities, primarily linked to BRIUMVI and related programs.

Market Cap: US$7.9b

TG Therapeutics has been positioned as a potential example of AstraZeneca’s call to move at Chinese speed, with BRIUMVI already commercial, a subcutaneous version in late stage development and early work in areas such as myasthenia gravis, progressive MS and treatment resistant schizophrenia. Revenue and earnings growth have been described as very strong, and profitability metrics such as a high net margin and ROE are notable. However, these figures are influenced by leverage, significant use of non cash earnings and a business model that relies heavily on a single drug. For investors, the appeal is a company that is expanding a proven franchise and returning capital through buybacks, while also facing concentrated product risk, funding risk and intense MS competition that could change the company’s trajectory.

TG Therapeutics’ rapid BRIUMVI ramp, strong headline profitability and heavy reliance on one drug create a powerful but fragile story, and the 3 key rewards and 1 important major warning sign could reveal what that mix is really hiding

Gilead Sciences (GILD)

Overview: Gilead Sciences is a large biopharmaceutical company that develops and sells treatments for HIV, liver diseases, cancer, serious infections and COVID-19, with a broad portfolio that includes oral drugs, injectables and cell therapies used in the United States, Europe and worldwide.

Operations: Gilead Sciences generates about US$29.7b in revenue from the discovery, development and commercialization of medicines, with US$21.1b from the United States, US$5.1b from Europe and US$3.5b from the rest of the world.

Market Cap: US$160.5b

Gilead Sciences sits at the center of the “Chinese speed” debate because it already runs a large, global platform in HIV and oncology while directing significant R&D investment to new regimens such as lenacapavir-based HIV prevention and once-weekly oral combinations that aim to reshape standard care. Investors see a mix of high current profitability, a 2.54% dividend and an expanding late-stage pipeline in areas such as Trodelvy for breast cancer. They also face exposure to high debt, heavy dependence on HIV therapies and near-term earnings pressure from deal-related costs. The tension between strong cash generation on one hand and risks related to patent cliffs and competition on the other is a key element of the current Gilead narrative.

Gilead Sciences looks like a cash engine that could be masking a bigger story, and the 5 key rewards and 1 important warning sign might be where the real tension between its pipeline and patent pressure finally shows its hand

The three Healthcare Innovation Leaders in this article are just a starting point. The full screen uncovers 7 more companies with equally compelling narratives inside the Healthcare Innovation Leaders screener. Use Simply Wall St to identify, analyze and filter for the precise catalysts and storylines that matter most so you can focus on the highest conviction healthcare ideas in minutes instead of hours.

Take Control of Your Investment Journey

If Gilead Sciences or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before The Crowd?

Fresh stock ideas can move from quiet to breakout quickly, and hesitation often means getting caught after the momentum is already flying. Scan these curated picks while it matters and consider your options promptly.

• Spot resilient businesses before they hit every headline by tracking companies in the 84 resilient stocks with low risk scores that aim to keep volatility in check while markets swing.
• Explore income opportunities that others may overlook by checking out the 9 dividend fortresses that highlights companies focusing on substantial yields with balance sheets designed to support them.
• Prepare for potential infrastructure developments by reviewing the 35 power grid technology and infrastructure stocks featuring companies connected to grid technology and electrical backbone projects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.